Lapka R, Marek J, Rejholec V, Franc Z
Eur J Clin Pharmacol. 1986;30(3):363-5. doi: 10.1007/BF00541546.
The pharmacokinetics of oral terguride 1 mg was evaluated in a single-dose study in 8 patients with a prolactinoma and one with acromegaly. A radioreceptor assay was used to measure the plasma levels of terguride. The peak plasma concentration (2.3 +/- 0.7 ng/ml, mean +/- SEM) was attained within 1 h of drug administration. Moment analysis gave a mean residence time of 4.3 +/- 0.6 h. Plasma prolactin was also determined by radioimmunoassay. The plasma prolactin was reduced to 30 +/- 3% of its pretreatment value after 4 h.
在一项单剂量研究中,对8例催乳素瘤患者和1例肢端肥大症患者评估了口服1毫克泰舒达的药代动力学。采用放射受体分析法测定血浆中泰舒达的水平。给药后1小时内达到血浆峰浓度(2.3±0.7纳克/毫升,平均值±标准误)。矩量法得出平均驻留时间为4.3±0.6小时。还通过放射免疫分析法测定血浆催乳素水平。4小时后,血浆催乳素降至治疗前值的30±3%。